Objective. To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE). Methods. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and/or cytotoxic drugs were enrolled in a prospective, nonrandomized study of CSA, Patients with hypertension or hypercreatinemia were excluded, Disease activity was evaluated according to the systemic lupus activity measure, Assessments were made prior to study entry and after 6, 12, 18, and 24 months. Results. Twenty-seven patients completed at least 24 months of treatment with CSA, The mean disease activity score significantly decreased after 6 months of therapy (P < 0.01); this result was maintained throughout the study, A conspicuous steroid-sparing effect was observed following administration of CSA (P < 0.01). Side effects included hypertrichosis (63% of patients), paresthesias (23%), gastrointestinal symptoms (20%), gingival hyperplasia (17%), hypertension (10%), tremors (7%), and nephrotoxicity (13%), No significant changes in serum creatinine Levels were observed. Conclusion. CSA represents a helpful second-choice treatment for patients with active SLE, Administration of CSA necessitates expert and careful followup of patients.

Long-term treatment of systemic lupus erythematosus with cyclosporin A / Domenico, Caccavo; Lagana', Bruno; Mitterhofer, Anna Paola; Ferri, Giovanni Maria; Antonella, Afeltra; Amoroso, Antonio; Lorenzo, Bonomo. - In: ARTHRITIS AND RHEUMATISM. - ISSN 0004-3591. - 40:1(1997), pp. 27-35. [10.1002/art.1780400106]

Long-term treatment of systemic lupus erythematosus with cyclosporin A

LAGANA', Bruno;MITTERHOFER, Anna Paola;FERRI, Giovanni Maria;AMOROSO, Antonio;
1997

Abstract

Objective. To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE). Methods. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and/or cytotoxic drugs were enrolled in a prospective, nonrandomized study of CSA, Patients with hypertension or hypercreatinemia were excluded, Disease activity was evaluated according to the systemic lupus activity measure, Assessments were made prior to study entry and after 6, 12, 18, and 24 months. Results. Twenty-seven patients completed at least 24 months of treatment with CSA, The mean disease activity score significantly decreased after 6 months of therapy (P < 0.01); this result was maintained throughout the study, A conspicuous steroid-sparing effect was observed following administration of CSA (P < 0.01). Side effects included hypertrichosis (63% of patients), paresthesias (23%), gastrointestinal symptoms (20%), gingival hyperplasia (17%), hypertension (10%), tremors (7%), and nephrotoxicity (13%), No significant changes in serum creatinine Levels were observed. Conclusion. CSA represents a helpful second-choice treatment for patients with active SLE, Administration of CSA necessitates expert and careful followup of patients.
1997
01 Pubblicazione su rivista::01a Articolo in rivista
Long-term treatment of systemic lupus erythematosus with cyclosporin A / Domenico, Caccavo; Lagana', Bruno; Mitterhofer, Anna Paola; Ferri, Giovanni Maria; Antonella, Afeltra; Amoroso, Antonio; Lorenzo, Bonomo. - In: ARTHRITIS AND RHEUMATISM. - ISSN 0004-3591. - 40:1(1997), pp. 27-35. [10.1002/art.1780400106]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/242305
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 110
  • ???jsp.display-item.citation.isi??? 81
social impact